Prior authorization & UM · Specialty medical-benefit PA
SamaCare
SamaCare is a medical-benefit prior authorization platform for specialty practices. It supports submission, tracking, and insights from real-world authorization data. It is not an enterprise payer UM suite for millions of covered lives.
Strong fit
- Specialty practices buried in prior authorizations for drugs covered under the medical benefit
- Groups that want submission, tracking, and insight into payer behavior in one place
- Groups that track time to a decision, approval rate, and how many patients start therapy
Weak fit
- Payers that need a large utilization management suite for medical and pharmacy across millions of members
- Primary care clinics with very few prior authorizations
- Buyers who will not change how staff handle problem cases after submission
Bottom line
SamaCare is worth using for specialty practices whose bottleneck is prior authorization for drugs covered under the medical benefit. It suits practices that will own the workflow. Practices that mainly need phone follow-up should look at Infinitus, and payers wanting enterprise review suites should look at Agadia or Xsolis.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
SamaCare is a prior authorization platform for drugs covered under the medical benefit, used inside specialty practice workflows.
It focuses on submission, tracking, and insights drawn from a large set of real-world authorizations. Its claims of faster decisions and higher approval rates are the ones to check.
It is narrower than Infinitus's voice automation and Agadia's PAHub for payers.
Setup is lighter than a health plan review suite but still needs a practice owner for the workflow.
Drug makers often support the cost rather than the practice paying a simple software price, which makes pricing less clear.
Among the prior authorization tools we review, SamaCare scores in the middle for a focused specialty fit.
Silna suits broader specialty care readiness work, and Infinitus suits practices missing phone follow-up. Payers comparing large review suites will usually look at Agadia or Xsolis.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Latent | 7.9 | 7.4 |
| Infinitus | 7.7 | 7.4 |
| Careviso | 7.6 | 7.3 |
| Silna Health | 7.3 | 7.1 |
| SamaCare | 7.1 | 7.0 |
| Develop Health | 7.0 | 6.8 |
| Valer | 6.6 | 6.4 |
| Linear Health | 6.5 | 7.0 |
Pricing
| Item | Detail |
|---|---|
| Model | Platform access for specialty practices, often paid for through drug maker partnerships. Terms vary. |
| What usually drives cost | Practice volume, drug areas, and whether drug maker programs cover access. |
| What to ask before you buy | Whether your practice pays directly, what service levels apply, and how your payer mix changes the cost. |
| Published pricing | SamaCare does not publish prices. Practices often get access through drug maker programs rather than a public price list. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get SamaCare to function | |
| Specialty practices with real prior authorization volume for medical-benefit drugs | Low volume makes the platform unnecessary. |
| Staff who will handle problem cases inside the prior authorization workflow | Automating only submission leaves denials unhandled. |
| Clarity on how practice access is funded | Drug maker funding needs clear terms. |
| A handoff path to your EHR or practice management system | Side portals that staff ignore fail. |
| Owners who track time to a decision and therapy starts | Without numbers, prior authorization tools become busywork. |
| What will maximize your value | |
| Track approval rate and days to resolution by payer | Those numbers justify the workflow change. |
| Keep human specialists on complex denials | Full autopilot on hard cases creates patient delays. |
| Use insights on payer behavior to change submission quality | Repeating the same missing data wastes cycles. |
| Drop duplicate fax and portal checklists after the switch | Parallel processes hide incomplete adoption. |
| Review patient churn tied to access delays | Access work is a retention problem as much as a billing one. |
| Deal-breakers | |
| You are a payer buying a large utilization management suite. | |
| Your practice has almost no prior authorization work for medical-benefit drugs. | |
| Staff will not change how they submit authorizations. | |
| Commercial terms for practice access are unclear and unacceptable. | |
| You need automated phone follow-up more than specialty prior authorization tools. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | From signing to kickoff | 1-4 weeks to settle access terms and map the workflow |
| 2 | From kickoff to first use | 3-8 weeks until the first specialties submit live |
| 3 | From first use to steady results | 2-4 months before approval rate gains level off |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.